PAB Shares Patrys Limited
ASX · ASXLast in our picks 2026-10-25 — not in the current list; analysis below is from that screen
Antibody therapeutics platform offers highly asymmetric upside from clinical and partnering progress.
Signal breakdown
- ▸Early-stage pipeline catalysts remain binary and speculative.
- ▾Below 50-day MA (-13.46%)
- ▸Volume 1.66× average — accumulation
- ▾Near 52-week low (7.4% of range)
Is PAB a buy right now?
Trend: PAB is trading below the 50-day average (-10.00%), RSI 52 — neutral momentum, with a 3-month return of -27.03%.
Valuation & quality: Patrys Limited trades on price-to-book 1.93; fundamentals show net margin 0.0%, return on equity -68.2%, revenue growth -93.2% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$0.13 (+381.5% vs the last close; range A$0.13 – A$0.13), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Antibody therapeutics platform offers highly asymmetric upside from clinical and partnering progress.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -25.00% | +0.00% | +66.70% | -20.00% | -25.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases.
Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.